Clinical Research Directory
Browse clinical research sites, groups, and studies.
Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients
Sponsor: Tanta University
Summary
This study aims to evaluate the efficacy and safety of telmisartan as a cardioprotective agent in patients receiving doxorubicin-based chemotherapy, with the goal of reducing treatment-associated cardiotoxicity, optimizing therapeutic outcomes, and facilitating the safer administration of anthracycline regimens.
Official title: Efficacy of Telmisartan in Preventing Doxorubicin-induced Cardiotoxicity in Breast Cancer Patients
Key Details
Gender
FEMALE
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
36
Start Date
2026-02
Completion Date
2027-02
Last Updated
2026-01-29
Healthy Volunteers
No
Interventions
Telmisartan
Telmisartan administered orally once daily as cardioprotective therapy during doxorubicin-based chemotherapy.
Doxorubicin (DOX)
Standard doxorubicin-based chemotherapy according to institutional protocol.
Locations (1)
Tanta University
Tanta, El Gharbia, Egypt